Patent SG-11201805621S-A (SG)
Title: Cancer vaccines
Inventor: BINDER JOSEPH JOHN
IPC: A61K39/00
Filed: 2017-01-16
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/125844 Al 27 July 2017 (27.07.2017) WIPO I PCT 11111111111111011101111111111101011111011101110111111111110111111111111111111110111111 (51) International Patent Classification: A61K 39/00 (2006.01) (21) International Application Number: PCT/IB2017/050229 (22) International Filing Date: 16 January 2017 (16.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/280,636 19 January 2016 (19.01.2016) US 62/419,190 8 November 2016 (08.11.2016) US (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors: BINDER, Joseph John; 12282 Cornwallis Square, San Diego, CA 92128 (US). CHO, Helen Kim; 4127 Twilight Ridge, San Diego, CA 92130 (US). COCKLE, Paul Jason; 126 Redwood Road, San An- selmo, CA 94960 (US). FALCONER, Derek John; 4651 Torrey Circle Apt K302, San Diego, CA 92130 (US). GURU, Siradanahalli; 10515 Abalone Landing Terrace, San Diego, CA 92130 (US). JOOSS, Karin Ute; 3712 Garden Lane, San Diego, CA 92106 (US). MARTINIC, Marianne Marcelo Andrea; 8623 Via Mallorca Unit C, La Jolla, CA 92037 (US). WILLS, Kenneth Nelson; 7806 Via Opuntia, Carlsbad, CA 92009 (US). (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 East 42nd Street, MS 235/9/S20, New York, NY 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the identity of the inventor (Rule 4.170) as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 17 / 125 8 44 Al (54) Title: CANCER VACCINES (57) : The present disclosure provides (a) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 poly- peptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (b) isolated nucleic acid molecules en- coding one or more immunogenic TAA polypeptides, (c) vaccine compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.